Hypogonadism is defined as reduced or absent secretion of testosterone which can lead to symptoms such as loss of libido, adverse changes in body composition, irritability and poor concentration.
“This agreement enables us to bring our innovative testosterone replacement product to Canadian patients and to continue to expand the reach of our Testim franchise outside the US,” said Armando Anido, CEO and president of Auxilium.
Under the agreement, Auxilium will be responsible for manufacturing and supplying Testim to Paladin. Paladin will be responsible for all sales, marketing and distribution activities in Canada. Financial details of the agreement were not disclosed.
Testim is approved for sale in 15 countries outside the US. Auxilium and Bayer of Canada recently agreed to mutually terminate their distribution agreement for Testim in Canada.